title: 125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors.
abstract: A series of 8-phenylxanthine derivatives has been synthesized with oxyacetic acid on the para phenyl position to increase aqueous solubility and minimize nonspecific binding and iodinatable groups on the 1- or 3-position of the xanthine ring. The structure-activity relationship for binding of these compounds to A1 adenosine receptors of bovine and rat brain and A2 receptors of human platelets was examined. The addition of arylamine or photosensitive aryl azide groups to the 3-position of xanthine had little effect on A1 binding affinity with or without iodination, whereas substitutions at the 1-position caused greatly reduced A1 binding affinity. The addition of an aminobenzyl group to the 3-position of the xanthine had little effect on A2 binding affinity, but 3-aminophenethyl substitution decreased A2 binding affinity. Two acidic 3-(arylamino)-8-phenylxanthine derivatives were labeled with 125I and evaluated as A1 receptor radioligands. The new radioligands bound to A1 receptors with KD values of 1-1.25 nM. Specific binding represented over 80% of total binding. High concentrations of NaCl or other salts increased the binding affinity of acidic but not neutral antagonists, suggesting that interactions between ionized xanthines and receptors may be affected significantly by changes in ionic strength. On the basis of binding studies with these antagonists and isotope dilution with the agonist [125I]N6-(4-amino-3-iodobenzyl)adenosine, multiple agonist affinity states of A1 receptors have been identified.
authors.affiliation: Department of Physiology, University of Virginia School of Medicine, Charlottesville 22908.
authors.forename: J
authors.initials: J
authors.lastname: Linden
authors.forename: A
authors.initials: A
authors.lastname: Patel
authors.forename: C Q
authors.initials: CQ
authors.lastname: Earl
authors.forename: R H
authors.initials: RH
authors.lastname: Craig
authors.forename: S M
authors.initials: SM
authors.lastname: Daluge
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D000262:Adenylyl Cyclases / Q000378:metabolism; D000345:Affinity Labels / Q000138:chemical synthesis* / Q000378:metabolism; D000465:Algorithms; D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002417:Cattle; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes / Q000378:metabolism*; D007553:Isotope Labeling; D007700:Kinetics; D008024:Ligands; D008566:Membranes / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011983:Receptors, Purinergic / Q000378:metabolism*; D012965:Sodium Chloride / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013806:Theophylline / Q000031:analogs & derivatives / Q000378:metabolism; D014970:Xanthines / Q000138:chemical synthesis* / Q000378:metabolism
chemical_list: D000345:Affinity Labels; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008024:Ligands; D011983:Receptors, Purinergic; D014970:Xanthines; D019830:Adenosine-5'-(N-ethylcarboxamide); D012965:Sodium Chloride; C044323:3-iodo-N(6)-4-aminobenzyladenosine; D013806:Theophylline; C028322:8-phenyltheophylline; D000262:Adenylyl Cyclases; D000241:Adenosine